Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

ABSTRACT The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 μg/ml and the MIC90s being <0.008 to 0.25 μg/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.

[1]  L. Hammitt,et al.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. , 2007, JAMA.

[2]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[3]  M. Pichichero,et al.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. , 2007, JAMA.

[4]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[5]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[6]  W. Schaffner,et al.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. , 2007, The Journal of infectious diseases.

[7]  S. Pelton,et al.  Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. , 2009, Vaccine.

[8]  D. Ecker,et al.  Occurrence, Distribution, and Origins of Streptococcus pneumoniae Serotype 6C, a Recently Recognized Serotype , 2008, Journal of Clinical Microbiology.

[9]  G. Talbot,et al.  In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.

[10]  W. Craig,et al.  Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target , 2006, Antimicrobial Agents and Chemotherapy.

[11]  Ronald N. Jones,et al.  Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[12]  Michael Martin,et al.  Invasive pneumococcal infections among vaccinated children in the United States. , 2010, The Journal of pediatrics.

[13]  M. Jacobs,et al.  Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Susan S. Huang,et al.  Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[15]  C. Whitney,et al.  Changes in Serotypes and Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Strains in Cleveland: a Quarter Century of Experience , 2008, Journal of Clinical Microbiology.

[16]  D. Rasko,et al.  Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005 , 2007, The Pediatric infectious disease journal.

[17]  J. Caillon,et al.  In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model , 2007, Antimicrobial Agents and Chemotherapy.

[18]  C. Whitney,et al.  Cost-Effectiveness of Pneumococcal Conjugate Vaccine: Evidence From the First 5 Years of Use in the United States Incorporating Herd Effects , 2006, The Pediatric infectious disease journal.

[19]  Ronald N. Jones,et al.  Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains , 2005, Antimicrobial Agents and Chemotherapy.

[20]  In Ho Park,et al.  Genetic Basis for the New Pneumococcal Serotype, 6C , 2007, Infection and Immunity.

[21]  Tanya Baculik.  CANVAS-1: Randomized, Double-blinded, Phase 3 Study (P903-06) of the Efficacy and Safety of Ceftaroline vs. Vancomycin plus Aztreonam in Complicated Skin and Skin Structure Infections (cSSSI) , 2008 .

[22]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .